Nestle S.A.

A new CEO is changing the Swiss giant's strategy, will the momentum be enough? 

Nestlé shares soared to their highest since 2008. The company will cut 6% of its workforce

Corporate chaos and falling sales: what's happening to the food giant?

The perfect storm for Nestlé: can the company get out of the crisis

The company's stock, which was already under pressure, fell due to increased uncertainty

Nestle's CEO, appointed a year ago, has been sacked over an office affair. This is a shock to the market

Bank of America sees the recent drawdown in Nestle shares as a good buying opportunity

Nestle has increased sales above forecast. Why does it want to sell some of its brands?

NIQ Global Intelligence

Preliminary trading in shares of NIQ Global Intelligence has begun on the Freedom client trading system. The securities of the global market leader in consumer analytics, known as NielsenIQ, are available under the ticker symbol <a href="https://tradernet.global/what-to-buy/stocks/NIQ.US">NIQ</a>. They will appear on the New York Stock Exchange later Wednesday.&nbsp;

NIQ IPO: shares of the analytics provider for Coca-Cola and Amazon begin trading


Novo Nordisk A/S

Eli Lilly and Company

Diabetes and obesity drugs based on semaglutide and tirzepatide - Ozempic, Wegowy, Zepbound and other hits from Danish Novo Nordisk and U.S.-based Eli lilly - are not only affecting the pharmaceutical market, but also other industries, including food production, restaurants and even clothing sales. In June, The Wall Street Journal <a href="https://www.wsj.com/business/retail/ozempic-clothing-sizes-weight-loss-80f9f83d">reported</a> on the sudden demand for clothes in small sizes, one of the reasons for which was the widespread availability of new weight-loss drugs;